Trials / Completed
CompletedNCT05420727
Theranostics in Soft Tissue Sarcoma Using a Vascular Disruption Approach
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 14 (actual)
- Sponsor
- John O. Prior · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
To test the feasibility of theranostic targeting the PSMA receptor in STS patients by Ga-68-PSMA-11 PET/CT and Lu-177-ITG-PSMA-1 treat-ment with special emphasis on vascular disruption using a translational approach.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Ga-68-PSMA-11 PET/CT | Ga-68-PSMA-11 PET/CT imaging |
| DRUG | Lu-177-ITG-PSMA-1 | Lu-177-ITG-PSMA-1 treatment |
Timeline
- Start date
- 2023-02-08
- Primary completion
- 2024-04-09
- Completion
- 2024-04-30
- First posted
- 2022-06-15
- Last updated
- 2024-06-18
Locations
1 site across 1 country: Switzerland
Source: ClinicalTrials.gov record NCT05420727. Inclusion in this directory is not an endorsement.